French
English
Part of the group is located at the Léon Bérard cancer center (around 15 peoples) and participates to the development of a translational research activity, in close collaboration with the clinicians of the radiotherapy department. These activities are based on methodological developments (deformable registration, tomographic reconstruction, particles-matter simulations) but are also at the source of innovative problems. After having been strongly involved in lung cancer radiotherapy studies as well as prostate cancer radiotherapy for US imaging guidance, we have started a collaboration with the Nuclear Medicine department (LUMEN) since a few years. Moreover, a strong collaboration was also established with the Medaustron hadrontherapy center in Austria. Those activities are supported by two main projects: Lyric (2012) and Lyrican (2018). Indeed, the CLB-HCL group was selected by INCA as an Integrated Cancer Research Site (SIRIC), with around 10M€ budget over 5 years. The project is led by JY Blay (director of CLB) and aims at strengthening multidisciplinary and translational research. Our group at CREATIS was deeply involved as leader of WP3 (Image Guided Local Treatments). It was renewed as Lyrican in 2018, entitled “Manipulating cell plasticity for innovative cancer treatment”. CREATIS coordinates the new WP3 dedicated to the physical and mathematical methods to analyse and overcome tumor plasticity at the macroscopic level for personalized treatment. Those two projects are the pillars of the translational activities of the group. In particular, the two projects fund a full-time research engineer (T. Baudier), dedicated to support software development, database maintenance and some data analysis for all translational activities of the group.